Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2024-02-06 Regulatory Filings
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2024-02-06 English
Cambio de categoría de consejero.
Board/Management Information Classification · 98% confidence The document is very short (997 characters) and announces a change in the status of a board member, D. Albert Grifols Coma-Cros, from 'consejero ejecutivo' (executive director) to 'consejero dominical' (non-executive director) due to stepping down from management functions. This directly relates to changes in the company's board of directors or senior management. This aligns perfectly with the definition for Board/Management Information (MANG). It is not a full report, nor is it a director's personal trade (DIRS) or a general regulatory filing (RNS), as it is highly specific to management structure.
2024-02-06 Spanish
FORM 6-K
Regulatory Filings
2024-02-05 English
Grifols anuncia cambios en su estructura de gobierno corporativo.
Board/Management Information Classification · 99% confidence The document is an official communication from Grifols, S.A., titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information), mandated by Spanish securities law (Ley 6/2023). The core content announces significant changes in the company's senior management structure: the departure of two executive officers (Raimon Grifols and Víctor Grifols Deu) from executive roles, the continuation of the Executive Chairman (Thomas Glanzmann), and the appointment of Nacho Abia as the new Chief Executive Officer (CEO). This directly relates to changes in the company's board of directors or senior management team. Therefore, the appropriate classification is Board/Management Information (MANG). The document is short and serves as an announcement, not a detailed report.
2024-02-05 Spanish
FORM 6-K
Regulatory Filings
2024-01-26 English
Como continuación de la comunicación presentada el 10 de enero.
Legal Proceedings Report Classification · 98% confidence The document is a formal communication from Grifols, S.A., referencing Spanish securities law (Ley 6/2023, artículo 227) to communicate 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The core content details the filing of a lawsuit in the U.S. District Court against parties responsible for a critical report (the 'Gotham report') alleging defamation and seeking damages. This communication is an update on a significant legal matter involving the company. Based on the definitions, 'Legal Proceedings Report' (LTR) is the most appropriate category for updates on significant lawsuits or regulatory actions.
2024-01-26 Spanish

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.